Unlimited Bio Founders Join Dr. Matt Kaeberlein on Optispan Podcast
On the Optispan Podcast, released on August 26, 2025, longevity scientist Dr. Matt Kaeberlein spoke with Ivan Morgunov and Anna Vakhrusheva, co-founders of Unlimited Bio, about the rise of offshore clinics accelerating gene therapy for aging.
Ivan Morgunov and Anna Vakhrusheva explained how Special Economic Zones (SEZs) like Próspera ZEDE (Roatán, Honduras) enable faster and more flexible trials than traditional regulatory systems. Their work focuses on muscle atrophy, immune decline, tissue repair, and extracellular matrix damage, with a combination therapy strategy that targets multiple hallmarks of aging at once.
The founders outlined an ambitious goal: 100 clinical trials in 10 years, positioning Unlimited Bio as a challenger to conventional biotech.
“Humanity cannot wait decades,” Dr.Vakhrusheva said. “By combining therapies, we can reprogram aging biology within our lifetime.”
They also emphasized the importance of Early Access for Patients. Offshore clinics open the door for early adopters to receive experimental therapies years before regulatory approval in the U.S. or Europe. While not without risks, this model allows collection of real-world data that could accelerate validation.
The discussion further touched on safety and ethical concerns. Kaeberlein challenged his guests on how to ensure patient protection, while they argued that transparent protocols, strong scientific foundations, and continuous monitoring are central to their approach.
Overall, the dialogue highlighted both the promise and the challenges of offshore innovation, underscoring Unlimited Bio’s role as one of the most dynamic forces shaping the future of longevity medicine.